SCHEMBL380073

SCHEMBL380073

Fc1ccccc1-c1nnc2cc(Br)ccn12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPK13 O15264 1/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
PDE2A O00408 3/20 0.36
PDE10A Q9Y233 3/20 0.36
POLB P06746 1/20 0.36
DCTPP1 Q9H773 1/20 0.36
MAPK14 Q16539 2/20 0.36
NOTUM Q6P988 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
GSK3B P49841 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10288930 0.83 DNMT1 (0.49) HSD11B1KDM4EMAPK13PDE2APDE10A
SCHEMBL3621998 0.82 HSD11B1 (0.40) HSD11B1KDM4EMAPK13PDE2APDE10A
SCHEMBL379749 0.82 HSD11B1 (0.48) HSD11B1KDM4EMAPK13PDE2APDE10A
SCHEMBL379692 0.82 HSD11B1 (0.52) HSD11B1KDM4EMAPK13PDE2APDE10A
SCHEMBL4076128 0.77 MAPK14 (0.44) HSD11B1KDM4EPDE2APDE10APOLB
SCHEMBL2023855 0.74 PDE2A (0.47) HSD11B1KDM4EPDE2APDE10APOLB
SCHEMBL9987840 0.70 DNMT1 (0.42) KDM4EPOLBMAPTSMN1; SMN2
SCHEMBL6775795 0.67 DCTPP1 (0.45) HSD11B1PDE2APDE10APOLBDCTPP1
SCHEMBL31096160 0.66 AHR (0.35) KDM4E
SCHEMBL31096117 0.66 AHR (0.36) KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086973-B1 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC (US) 2012-01-25 EP disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
EP-2086973-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF Amgen Inc., (US) 2009-08-12 EP disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
WO-2008045393-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof MAPK1, MAP3K1, MAP3K7 HSD11B1 2370/4885KDM4E 2389/4885MAPK13 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.